Axsome Therapeutics to Acquire Jazz Pharmaceuticals’ Sleep-Combating Drug Sunosi

Jazz Pharmaceuticals agreed to divest its Sunosi (solriamfetol) drug to Axsome Therapeutics that includes an upfront payment of $53 million.

Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor that has FDA and EU approval for treatment of excessive daytime sleepiness due to narcolepsy and obstructive sleep apnea.

Jazz earned $57.9 million from Sunosi sales in 2021, an increase of 104 percent from the previous year.